Cargando…
抗血管生成药物联合EGFR-TKI治疗EGFR突变晚期非小细胞肺癌的研究进展
Lung cancer is one of the leading causes of cancer-related morbidity and mortality. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) have become the standard treatment for EGFR-mutated advanced non-small cell lung cancer (NSCLC). Unfortunately, drug resistance is inevitable in m...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411955/ https://www.ncbi.nlm.nih.gov/pubmed/36002195 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.41 |